Sign up
Pharma Capital

VentriPoint Diagnostics shares tick higher as it hires new marketing manager

The firm's VMS Plus device is an accurate AI (artificial intelligence) tool for measuring whole-heart function
1539874497_heart.jpg
The firm's technology allows medics to assess whole heart function

Shares in heart-imaging specialist VentriPoint Diagnostics Ltd (CVE:VPT) ticked higher on Thursday as it revealed it had a new marketing manager and gave an update on sales.

Jessica Naman will be responsible for marketing strategies that drive revenue, the med-tech group said. The firm's VMS Plus device is an accurate AI (artificial intelligence) tool for measuring whole-heart function using conventional ultrasound.

Naman will be leading the team in the pre-launch plan as the company showcases the next-generation system at EuroEcho 2018 in Milan, Italy, this December and will explore further opportunities in the future of 3-D heart analysis using conventional 2-D ultrasound technologies, said Ventripoint.

Proven track record

"With 15 years of experience in marketing for technology-based companies, most recently in the medical device industry, she brings a proven track record in the development and management of comprehensive marketing campaigns, which integrate a strategic approach to public relations, social media, conferences and events," said Desmond Hirson, president of Ventripoint.

Notably, Ventripoint said it had secured two new orders for its VMS Plus heart analysis products at leading hospitals in Germany and the USA.

A further cardiac centre in Canada is in the final stages of institutional sign-offs prior to issuing a purchase order, it added.

"The sales funnel has also expanded with 12 clinical studies being planned to show the merits of the VMS Plus approach to cardiac analysis in specific heart conditions, including pregnancy, stress tests, right heart failure, left heart failure, along with congenital heart disease in children and adults, and pulmonary hypertension," the company said in a regulatory statement.  

"In addition, the company's sales team will be delivering several presentations to pediatric cardiologists across North America and Europe on the VMS Plus products."

Shares added 3.13% to stand at $0.155 each.

Giles_55af4ddca6481.jpg


Register here to be notified of future VPT Company articles
View full VPT profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.